The New York Times is looking to speak with people who are about to start GLP-1 medications such as Ozempic and are open to allowing us to chronicle their experiences.
Have you tried numerous avenues to help your chronic illness, obesity or mental health and turned to Ozempic, Wegovy or another GLP-1 drug to address these issues? The New York Times wants to chronicle the journeys of people who are about to start taking one of these medications or who are losing access to them. We’re especially interested in hearing from groups of people, such as friends or families, that are taking these drugs as a group.
We will keep all responses confidential and will reach out to respondents whose stories we’d like to learn more about. We will only use your contact information to follow up with you and will not share it outside the Times newsroom.
Source: Elections - nytimes.com
